- Home
- LRMR
as 05-30-2025 4:00pm EST
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BALA CYNWYD |
| Market Cap: | 183.8M | IPO Year: | N/A |
| Target Price: | $19.63 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.61 - $11.20 | Next Earning Date: | 04-30-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Larimar Therapeutics Inc. News
LRMR Breaking Stock News: Dive into LRMR Ticker-Specific Updates for Smart Investing
GOBankingRates
14 hours ago
7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs
GOBankingRates
14 hours ago
3 International Vacations That Are Cheaper Than an iPhone
GOBankingRates
14 hours ago
Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck
Yahoo Finance
14 hours ago
This week in Trumponomics: Too bad TACO isn’t true
The Guardian
14 hours ago
Starmer says Farage would spook the City and give us Truss 2 – he could be right
Yahoo Finance Video
14 hours ago
AI ecosystem isn't just Nvidia: Unlock it further with this ETF
Benzinga
14 hours ago
Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?
Reuters
14 hours ago
Ford recalls more than 29,000 vehicles in the US, NHTSA says
Compare LRMR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LRMR Larimar Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.